Search
Chlorotoxin I-131
go.drugbank.com/drugs/DB05462InvestigationalChlorotoxin I-131 is investigated in clinical trials for treating brain cancer. … Chlorotoxin is a small 36-amino-acid peptide that selectively binds to glioma cells but not normal brain parenchyma.
Categories: Complex MixturesNovobiocin
go.drugbank.com/drugs/DB01051ApprovedInvestigationalVet approvedWithdrawnNovobiocin is an antibiotic compound derived from _Streptomyces niveus_. It has a chemical structure similar to coumarin.
Anpocogin
go.drugbank.com/drugs/DB06552InvestigationalRecombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity. [A175642]
Magnesium trisilicate
go.drugbank.com/drugs/DB09281ApprovedMagnesium trisilicate is an inorganic compound that is used as an antacid in the treatment of peptic ulcers.
Mixtures: NEUTROSE S. PELLEGRINO, NEUTROSE S. PELLEGRINOBevirimat
go.drugbank.com/drugs/DB06581InvestigationalBevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. … It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.
N-methylnicotinamide
go.drugbank.com/drugs/DB08840InvestigationalIt is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine … N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation.
Afelimomab
go.drugbank.com/drugs/DB04956ExperimentalAfelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis.
Narlaprevir
go.drugbank.com/drugs/DB14760InvestigationalCategories: Antivirals for Systemic Use, Antiinfectives for Systemic UseMBT-0312
go.drugbank.com/drugs/DB05880ExperimentalMediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.